Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PISARSCOV

Financiado

Cerrado

SEVERE ACUTE RESPIRATORY SYNDROME SARS DESIGN SYNTHESIS IDENTIFICATION AND...

SEVERE ACUTE RESPIRATORY SYNDROME SARS DESIGN SYNTHESIS IDENTIFICATION AND EVALUATION OF NOVEL NON PEPTIDIC INHIBITORS OF MAIN PROTEASE EMPLOYING DYNAMIC LIGATION SCREENING DLS The Severe Acute Respiratory Syndrome (SARS) emerged in 2003 in Asia, and within a few months infected 8500 people world and caused more than 800 deaths. This novel medical condition is a viral respiratory illness caused by the SA... ver más

28/02/2011

FORSCHUNGSVERBUND...

170K€

Presupuesto del proyecto: 170K€

Líder del proyecto

FORSCHUNGSVERBUND BERLIN EV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2011-02-28 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

FORSCHUNGSVERBUND BERLIN EV

0.00€ | Lider

Proyectos interesantes

SPOTLESS

Medical Technol...

Data Science

257K€ Cerrado

glyCoVdrugs

Medical Technol...

Pharmaceutical...

Cerrado

Inhibicov

Medical Technol...

Data Science

150K€ Cerrado

PID2021-123332OB-C21

Medical Technol...

Data Science

157K€ Cerrado

EXSCALATE4CoV

Medical Technol...

Data Science

3M€ Cerrado

EEBB-I-12-05513

Medical Technol...

Data Science

5K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

FORSCHUNGSVERBUND BERLIN EV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 170K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The Severe Acute Respiratory Syndrome (SARS) emerged in 2003 in Asia, and within a few months infected 8500 people world and caused more than 800 deaths. This novel medical condition is a viral respiratory illness caused by the SARS-associated coronavirus (SARS-CoV). And at present, no efficacious therapy is available, for these reason finding a useful drug candidate against SARS corona virus is a goal with high scientific, technological and socio-economic interest. Our (and other´s) preliminary results indicate that the viral protease is an excellent target for the treatment of coronaviral infections. In order to obtain new active SARS-CoV molecules as main protease inhibitors Dynamic Ligation Screenig (DLS) methodology will be developed. This new approach combines dynamic, target-assisted formation of inhibitory species and detection by fluorescence-based screening methodology. In addition to use an enzymatic reaction for fragment detection amplifies the signals and thus reduces the required amount of protein drastically. Finally, enzymatic detection via a fluorescent reporter molecule should enable high-throughput screening (HTS) in microtiter plates. Based on preliminary results, the synthesis of structural analogues of peptide-aldehydes, that containing in the C-terminal extreme other functionalities, will be synthesized. The reaction of these analogues of peptide-aldehydes, acting as directing probe, with a library of amines, carboxylic acid and isocyanides in presence of the enzyme, their substrate in water through Mannich and Ugi reactions provides -amino carbonyl and -N-acylamino amides compounds. The analysis of the crude reaction mixtures will be carried out employing fluorescence assay and it will be allowed us find active fragments (Hits). In these cases, it will be transform through reversed screen until obtain one non-peptidic inhibitor. Finally, molecular modelling studies will be realized to determinate both structure-activity relationship.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores